Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Japán
8 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Bunkyo, Chiba, Chūō, Fukuoka, Hiroshima, Iruma-gun, Isehara, Kanazawa, Kashiwa, Kobe, Kyoto, Matsuyama, Miyazaki, Nagoya, Okayama, Osaka, Sakai, Sendai, Yamagata
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Chiba, Okayama, Tokyo
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 2/3. fázisTaking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Bunkyo, Chūō, Fukuoka, Fukushima, Hirakata, Isehara, Kyoto, Minato, Miyazaki, Osaka, Sapporo, Tsu, Yamagata
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - 2. fázisTaking peopleA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Where
- Bunkyo, Chūō, Hirakata, Izumo, Nagasaki, Nagoya, Sapporo, Sendai, Toyoake
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Kashiwa
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Chiba, Kashiwa, Kōtoku, Nagoya, Yokohama
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 3. fázisTaking peopleStudy of Out of Specification for Tisagenlecleucel
- Where
- Aomori, Bunkyo Ku, Chiba, Chuo Ku, Fuchū, Fukuoka, Gifu, Hamamatsu, Hiroshima, Ishikawa, Izumi, Izumisano, Izumo, Kita-gun, Kobe, Kumamoto, Kurashiki, Kyoto, Matsumoto, Minato Ku, Nagasaki, Nagoya, Niigata, Nishinomiya, Okayama, Osaka, Saitama, Sakai, Sapporo, Sendai, Setagaya-ku, Shinjuku Ku, Suita, Tōon, Tsu, Tsukuba, Wakayama, Yokohama, Yufu
- Életkor
- 0 év to 100 év
- People
- 200 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04094311 - 2. fázisTaking peopleDALY II Japan/MB-CART2019.1 for DLBCL
- Where
- Tokyo
- Életkor
- 18 év and over
- People
- 31
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT07288879